PHG.F PHARMING GRP SP. ADRS

Healthcare Biotechnology Frankfurt Exchange
11.40 EUR
Close of Nov 12, 2026
7.70 17.40
Market cap
EUR 807M
P/E
40.7x
P/B
3.07x
ROE
8.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PHG.F undervalued?

Graham number
Price11.40
Graham value4.84
Premium135.6%

PHG.F trades 135.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PHARMING GRP SP. ADRS fundamental analysis

No fundamental analysis for PHARMING GRP SP. ADRS yet.

PHARMING GRP SP. ADRS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PHARMING GRP SP. ADRS

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treat…

Full company profile